Stocks / NASDAQ / Sage Therapeutics, Inc.

Sage Therapeutics, Inc.

Our Opinion

Sage Therapeutics is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical research and development.

Supporting Evidence:

The company stated in the following press release that they conduct pre-clinical trials of their drugs on animals.

“In preclinical development, SAGE-217 demonstrated anti-seizure and anxiolytic activity in multiple animal models, including potent activity in seizure models such as Dravet and Fragile X syndromes.” Read the following article

Company Description

SAGE Therapeutics, Inc., incorporated on April 16, 2010, is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. [Source: Reuters]

Company Website: